RxDoctor Payments Data

Dat Nguyen, MD

Internal Medicine · Hawthorne, CANPI 1720092315

Payments from drug & device makers

$969in general payments, 2019–2025

Across 37 payments — averaging $26.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$439
  • Acadia Pharmaceuticals Inc$147
  • Pfizer$94
  • Amgen$67
  • Novo Nordisk$60
  • Redhill Biopharma Inc.$54
  • plus $109 from 4 others

What the payments were for

  • Food & beverage$969100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$969 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$375,623
Medicare patients
473
Services billed
4,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate23$144,351
EliquisApixaban160$65,189
FarxigaDapagliflozin Propanediol22$10,294
RestasisCyclosporine19$10,203
RytaryCarbidopa/Levodopa31$9,474
JanuviaSitagliptin Phosphate25$8,834
LinzessLinaclotide17$8,745
Sucralfate89$6,936
Meropenem56$6,388
Memantine Hcl228$5,711
XareltoRivaroxaban18$5,647
BrilintaTicagrelor25$5,604
DapagliflozinDapagliflozin Propanediol15$5,203
Mirtazapine192$4,881
JardianceEmpagliflozin19$4,860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$94$65,189160 claims
MerckJanuvia$15$8,83425 claims
Johnson & JohnsonXarelto$439$5,64718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Hawthorne

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →